An Open-Label Study to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Homozygous Familial Hypercholesterolemia
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 04 Dec 2019
Price : $35 *
At a glance
- Drugs Alirocumab (Primary) ; Atorvastatin; Colestyramine; Ezetimibe; Fenofibrate; Fluvastatin; Lovastatin; Nicotinic acids; Omega-3-fatty-acid; Pravastatin; Rosuvastatin; Simvastatin
- Indications Hyperlipoproteinaemia type IIa
- Focus Registrational; Therapeutic Use
- Sponsors Sanofi
- 02 Dec 2019 Planned primary completion date changed from 1 Sep 2019 to 1 Feb 2020.
- 26 Sep 2019 Planned primary completion date changed from 1 Aug 2019 to 1 Sep 2019.
- 05 Jun 2019 Status changed from recruiting to active, no longer recruiting.